EP2089014A4 - Acides gras oméga-3 et agent dyslipidémique pour la réduction des niveaux d'apo-b - Google Patents
Acides gras oméga-3 et agent dyslipidémique pour la réduction des niveaux d'apo-bInfo
- Publication number
- EP2089014A4 EP2089014A4 EP07852630A EP07852630A EP2089014A4 EP 2089014 A4 EP2089014 A4 EP 2089014A4 EP 07852630 A EP07852630 A EP 07852630A EP 07852630 A EP07852630 A EP 07852630A EP 2089014 A4 EP2089014 A4 EP 2089014A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- apo
- omega
- levels
- reduction
- fatty acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US85028006P | 2006-10-10 | 2006-10-10 | |
PCT/US2007/021631 WO2008045465A1 (fr) | 2006-10-10 | 2007-10-10 | Acides gras oméga-3 et agent dyslipidémique pour la réduction des niveaux d'apo-b |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2089014A1 EP2089014A1 (fr) | 2009-08-19 |
EP2089014A4 true EP2089014A4 (fr) | 2009-12-09 |
Family
ID=39283166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07852630A Withdrawn EP2089014A4 (fr) | 2006-10-10 | 2007-10-10 | Acides gras oméga-3 et agent dyslipidémique pour la réduction des niveaux d'apo-b |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2089014A4 (fr) |
JP (1) | JP2010505956A (fr) |
KR (1) | KR20090080070A (fr) |
CN (2) | CN101553221A (fr) |
AU (1) | AU2007307007A1 (fr) |
BR (1) | BRPI0719182A2 (fr) |
CA (1) | CA2672919A1 (fr) |
EA (2) | EA018734B1 (fr) |
MX (1) | MX2009003921A (fr) |
WO (1) | WO2008045465A1 (fr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8784886B2 (en) | 2006-03-09 | 2014-07-22 | GlaxoSmithKline, LLC | Coating capsules with active pharmaceutical ingredients |
JP2010506920A (ja) * | 2006-10-18 | 2010-03-04 | リライアント・ファーマシューティカルズ・インコーポレイテッド | Lp−pla2濃度を減少させるためのオメガ−3脂肪酸 |
EP3578177A1 (fr) | 2008-09-02 | 2019-12-11 | Amarin Pharmaceuticals Ireland Limited | Composition pharmaceutique contenant de l'acide eicosapentaénoïque et leurs procédés d'utilisation |
PT2395991E (pt) | 2009-02-10 | 2013-09-03 | Amarin Pharmaceuticals Ie Ltd | Utilização de éster etílico de ácido eicosapentaenóico para tratamento de hipertrigliceridemia |
NZ627238A (en) | 2009-04-29 | 2016-02-26 | Amarin Pharmaceuticals Ie Ltd | Stable pharmaceutical composition comprising ethyl eicosapentaenoate |
NZ789295A (en) | 2009-04-29 | 2024-02-23 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
CN114053258A (zh) * | 2009-06-15 | 2022-02-18 | 阿马里纳药物爱尔兰有限公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法 |
SG10201405994UA (en) | 2009-09-23 | 2014-10-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
NZ778131A (en) | 2010-11-29 | 2023-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
WO2013070735A1 (fr) | 2011-11-07 | 2013-05-16 | Amarin Pharmaceuticals Ireland Limited | Méthodes de traitement de l'hypertriglycéridémie |
AU2013207368A1 (en) | 2012-01-06 | 2014-07-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject |
JP2015522029A (ja) | 2012-06-29 | 2015-08-03 | アマリン ファーマシューティカルス アイルランド リミテッド | スタチン療法中の患者における心血管系イベントの危険性を減少させる方法 |
CN102824636A (zh) * | 2012-08-15 | 2012-12-19 | 四川大学 | 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途 |
WO2014034871A1 (fr) * | 2012-08-30 | 2014-03-06 | 株式会社 三和化学研究所 | Médicament pour la prévention ou le traitement de la dyslipidémie |
US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
LT3102212T (lt) * | 2014-02-05 | 2019-02-25 | Dezima Pharma B.V. | Cholesterilo esterio pernešimo baltymo (cetp) inhibitorius ir farmacinės kompozicijos, apimančios minėtą inhibitorių, skirtos panaudoti širdies ir kraujagyslių ligų gydymui arba prevencijai |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
WO2018213663A1 (fr) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions et méthodes pour dimunuer les triglycérides chez un sujet ayant une fonction rénale réduite |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
CN112218630A (zh) | 2018-09-24 | 2021-01-12 | 阿马里纳药物爱尔兰有限公司 | 降低受试者的心血管事件的风险的方法 |
WO2022225896A1 (fr) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Procédés de réduction du risque d'insuffisance cardiaque |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030170643A1 (en) * | 1999-10-26 | 2003-09-11 | Edward Fisher | Regulation of apoB treatment and drug screening for cardiovascular and metabolic disorders or syndromes |
WO2007011886A2 (fr) * | 2005-07-18 | 2007-01-25 | Reliant Pharmaceuticals, Inc. | Traitement au moyen d'inhibiteurs d'absorption de cholesterol a base d'azetidinone et d'acide gras omega-3 et produit de combinaison de ceux-ci |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101356335B1 (ko) * | 2004-12-06 | 2014-02-06 | 릴라이언트 파마슈티컬스 인코퍼레이티드 | 지질 치료를 위한 오메가-3 지방산 및 이상지질혈증 제제 |
-
2007
- 2007-09-07 CN CNA2007800456489A patent/CN101553221A/zh active Pending
- 2007-09-07 EA EA200970359A patent/EA018734B1/ru not_active IP Right Cessation
- 2007-10-10 WO PCT/US2007/021631 patent/WO2008045465A1/fr active Application Filing
- 2007-10-10 AU AU2007307007A patent/AU2007307007A1/en not_active Abandoned
- 2007-10-10 EA EA200970360A patent/EA200970360A1/ru unknown
- 2007-10-10 CA CA002672919A patent/CA2672919A1/fr not_active Abandoned
- 2007-10-10 MX MX2009003921A patent/MX2009003921A/es unknown
- 2007-10-10 EP EP07852630A patent/EP2089014A4/fr not_active Withdrawn
- 2007-10-10 CN CNA2007800456667A patent/CN101553220A/zh active Pending
- 2007-10-10 BR BRPI0719182-0A2A patent/BRPI0719182A2/pt not_active Application Discontinuation
- 2007-10-10 KR KR1020097009523A patent/KR20090080070A/ko not_active Application Discontinuation
- 2007-10-10 JP JP2009532391A patent/JP2010505956A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030170643A1 (en) * | 1999-10-26 | 2003-09-11 | Edward Fisher | Regulation of apoB treatment and drug screening for cardiovascular and metabolic disorders or syndromes |
WO2007011886A2 (fr) * | 2005-07-18 | 2007-01-25 | Reliant Pharmaceuticals, Inc. | Traitement au moyen d'inhibiteurs d'absorption de cholesterol a base d'azetidinone et d'acide gras omega-3 et produit de combinaison de ceux-ci |
Non-Patent Citations (4)
Title |
---|
CHAN ET AL: "Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia", DIABETES,, vol. 51, 1 January 2002 (2002-01-01), pages 2377 - 2386, XP008108930 * |
DURRINGTON P N ET AL: "An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased trigycerides in simvastatin treated patients with coronary heart disease and persisting hyperlipidemia", HEART, BMJ, LONDON, GB, vol. 85, 1 January 2001 (2001-01-01), pages 544 - 548, XP003011854, ISSN: 1355-6037 * |
NORDOY ET AL: "n-3 fatty acids as supplement to statins in the treatment of patients with combined hyperlipidemia'", ESSENTIAL FATTY ACIDS AND EICOSANOIDS: INVITED PAPERS FROM THEINTERNATIONAL CONGRESS, XX, XX, 1 January 1998 (1998-01-01), pages 256 - 261, XP008081086 * |
See also references of WO2008045465A1 * |
Also Published As
Publication number | Publication date |
---|---|
EA018734B1 (ru) | 2013-10-30 |
MX2009003921A (es) | 2009-08-31 |
CN101553221A (zh) | 2009-10-07 |
BRPI0719182A2 (pt) | 2014-10-21 |
WO2008045465A1 (fr) | 2008-04-17 |
CA2672919A1 (fr) | 2008-04-17 |
CN101553220A (zh) | 2009-10-07 |
AU2007307007A1 (en) | 2008-04-17 |
EA200970360A1 (ru) | 2009-10-30 |
EA200970359A1 (ru) | 2009-10-30 |
JP2010505956A (ja) | 2010-02-25 |
KR20090080070A (ko) | 2009-07-23 |
EP2089014A1 (fr) | 2009-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2089014A4 (fr) | Acides gras oméga-3 et agent dyslipidémique pour la réduction des niveaux d'apo-b | |
EP2083815A4 (fr) | Statine et acides gras oméga-3 pour la réduction des niveaux d'apo-b | |
EP2083622A4 (fr) | Procédés d'utilisation d'acides gras oméga-3 pour réduire les taux de lp-pla2 | |
EP1830830A4 (fr) | Acides gras omega-3 et agent dyslipidemique pour therapie lipidique | |
EP1904049A4 (fr) | Acides gras polyinsatures pour le traitement de la demence et d'etats predementiels | |
ZA201003030B (en) | Medium-chain length fatty acids and glycerides as nephroprotection agents | |
IL183246A0 (en) | Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same | |
EP2120920A4 (fr) | Oxylipines derivées d'acides gras polyinsaturés à chaîne longue et leurs procédé de production et d'utilisation | |
EP2061335A4 (fr) | COMPOSITION À BASE D'HUILE GLYCÉRIDiQUE DÉRIVÉE D'HUILE DE POISSON ET SON PROCÉDÉ DE PRÉPARATION | |
HK1105871A1 (en) | Composition containing statins and omega-3 fatty acids | |
EP2046957A4 (fr) | Désaturases d'acides gras et leurs utilisations | |
IL190715A0 (en) | Triazolopyridine derivatives as inhibitors of lipases and phospholipases | |
EP2041047A4 (fr) | Melanges d'acides gras et leurs utilisations | |
GB2443926B (en) | Electronic candle and method of use | |
EP2059588A4 (fr) | Synthèse d'acides gras | |
ZA200702280B (en) | Fatty acid esters of alkanolamines and their use as softening agents | |
EP2136844A4 (fr) | Compositions comprenant des monoglycérides d'acides gras polyinsaturés ou des dérivés de ceux-ci et leurs utilisations | |
PL1755565T3 (pl) | Miękka kapsułka żelatynowa zawierająca wielonienasycony kwas tłuszczowy omega-3 | |
ZA200807341B (en) | Fatty acid by-products and methods of using same | |
HK1115373A1 (en) | Intermolecular compound of fatty acid triglyceride | |
IL190728A0 (en) | Intravenous essential fatty acid emulsion | |
ZA200807296B (en) | Fatty acid by-products and methods of using same | |
EP2114397A4 (fr) | Nouveaux conjugués d'acides gras poly-insaturés avec des amines et utilisations thérapeutiques de ceux-ci | |
PL2390339T3 (pl) | Delta-8 desaturazy i ich zastosowanie w wytwarzaniu polinienasyconych kwasów tłuszczowych | |
EP2099295A4 (fr) | Prophylaxie et traitement de la fibrillation auriculaire avec des acides gras oméga-3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090507 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: HR |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20091110 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/366 20060101ALI20091104BHEP Ipc: A61P 9/00 20060101ALI20091104BHEP Ipc: A61P 3/06 20060101ALI20091104BHEP Ipc: A61K 31/351 20060101ALI20091104BHEP Ipc: A61K 31/232 20060101ALI20091104BHEP Ipc: A61K 31/20 20060101AFI20080523BHEP |
|
RAX | Requested extension states of the european patent have changed |
Extension state: HR Payment date: 20090507 |
|
17Q | First examination report despatched |
Effective date: 20100212 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100824 |